re.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care – neotiv Reports
28 Julio 2024 - 7:00PM
Business Wire
At the Alzheimer’s Association International Conference
(AAIC) from July 28th to August 1st, 2024 in Philadelphia/USA, the
results of the real-world application study re.cogni.ze were
presented for the first time. The study, initiated by Roche and
conducted in cooperation with the digital health company neotiv,
examined the user-friendliness, adherence, and acceptance of
digital early detection of mild cognitive impairment (MCI: ICD-10
Code F06.7). Early detection of MCI is a prerequisite for the
diagnosis of Alzheimer’s disease. The re.cogni.ze study shows: The
neotivCare app is suitable for early detection at all levels of
medical care and offers added value compared to conventional
methods. The study results are of international significance and
are particularly relevant for regions in which treating early-stage
Alzheimer’s with medication has already received regulatory
approval – e.g. in the United States.
The application study re.cogni.ze is the largest study on the
digital early detection of mild cognitive impairment in primary and
specialized healthcare in Germany. Over a study period of 22
months, 27 neurologists and psychiatrists in private practice, 13
general practitioners (GPs) and three memory clinics, as well as
765 patients, were included in the prospective, multi-center
study.
As part of the study, patients with subjectively perceived
memory problems were prescribed the neotivCare app by their
attending physician. Over a period of twelve weeks, they used the
app to carry out weekly tests and self-assessments. This was done
independently at home after an uncomplicated introduction to the
app. At the end of the test period, the app created a letter of
findings for the patients, which served as the basis for discussing
the findings with their attending physician.
High patient satisfaction
Adherence among patients who activated the neotivCare app as
part of the study is 93 percent. 67.6 percent report added value
from the app, 51 percent state that using the app has reduced their
worries.
FULL TEXT press release:
https://mediaserver.frauwenk.de/neotiv/20240728_Pressemitteilung_re.cogni.ze_AAIC_EN.pdf
About neotiv
neotiv GmbH was founded in 2017 and is headquartered in
Magdeburg with an additional office in Berlin. The digital health
company is a spin-off of the OVGU Magdeburg in close cooperation
with the German Center for Neurodegenerative Diseases (DZNE).
www.neotiv.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240728520146/en/
neotiv
Julian Haupenthal Chief Product Officer +49 175
9823543
Silvio Riese Head of Commercial Operations +49 176
81113810 presse@neotiv.com